0001493152-24-001971.txt : 20240110 0001493152-24-001971.hdr.sgml : 20240110 20240110171709 ACCESSION NUMBER: 0001493152-24-001971 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240108 FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gagnon Robert E. CENTRAL INDEX KEY: 0001504983 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40899 FILM NUMBER: 24527279 MAIL ADDRESS: STREET 1: C/O BIOGEN IDEC INC. STREET 2: 133 BOSTON POST ROAD CITY: WESTON STATE: MA ZIP: 02493 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bone Biologics Corp CENTRAL INDEX KEY: 0001419554 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 421743430 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 BURLINGTON WOODS DRIVE, STREET 2: SUITE 100, CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: (781) 552-4452 MAIL ADDRESS: STREET 1: 2 BURLINGTON WOODS DRIVE, STREET 2: SUITE 100, CITY: BURLINGTON STATE: MA ZIP: 01803 FORMER COMPANY: FORMER CONFORMED NAME: Bone Biologics, Corp. DATE OF NAME CHANGE: 20140924 FORMER COMPANY: FORMER CONFORMED NAME: AFH ACQUISITION X, INC. DATE OF NAME CHANGE: 20071127 4 1 ownership.xml X0508 4 2024-01-08 0 0001419554 Bone Biologics Corp BBLG 0001504983 Gagnon Robert E. C/O BONE BIOLOGICS CORP BURLINGTON WOODS DR. SUITE 100 BURLINGTON MA 01803 1 0 0 0 0 Non-Employee Stock Option 4.68 2024-01-08 4 A 0 9 0.00 A 2034-01-08 Common Stock 9 9 D Non-Employee Stock Option 4.68 2024-01-08 4 A 0 8.006 0.00 A 2034-01-08 Common Stock 8006 8015 D This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, 2,003 options are immediately exercisable with the remaining 6,003 options vesting and becoming exercisable in three equal installments on 3/12/2024, 6/12/2024, and 9/12/2024. /s/ Robert E. Gagnon 2024-01-10